Interventional cardiology in a whole new light

Open menu

News & Events

OPSENS RECEIVES FDA 510(K) CLEARANCE FOR THE OPTOWIRE II

16 March 2016

Quebec City, Quebec, March 16, 2016 – Opsens Inc. (“Opsens” or the “Company”) (TSXV:OPS) (OTCQX:OPSSF) today announces the 510(k) clearance from the U.S. Food and Drug Administration (“FDA“) for the OptoWire II, an optical guidewire developed to measure Fractional Flow Reserve (“FFR“). FFR measurement is used for the diagnostic of the severity of coronary stenosis…

Read more

OPSENS NAMED TO THE 2016 TSX VENTURE TOP 50®

10 March 2016

OPSENS Named to THE 2016 TSX Venture TOP 50® Quebec City, Quebec, March 8, 2016 – Opsens Inc. (“Opsens” or the “Company”) (TSXV:OPS) (OTCQX:OPSSF) is pleased to announce that it has been recognized in the top performing Technology companies in the 2016 TSX Venture 50®. The TSX Venture 50® ranks the top 10 companies in…

Read more